Anti-CD20 monoclonal antibody therapy in multiple myeloma
作者： Prashant Kapoor , Patricia T. Greipp , William G. Morice , S. Vincent Rajkumar , Thomas E. Witzig
DOI: 10.1111/J.1365-2141.2008.07024.X
关键词:
摘要: … in myeloma because of recent studies suggesting the existence of clonogenic CD20-positive … and clinical activity of anti-CD20 therapy in myeloma. Clinical trials show that anti-CD20 …
elsevier.com
sci-hub.se 参考文章(123)
P. Feugier, A. Van Hoof, C. Sebban, P. Solal-Celigny, R. Bouabdallah, C. Fermé, B. Christian, E. Lepage, H. Tilly, F. Morschhauser, P. Gaulard, G. Salles, A. Bosly, C. Gisselbrecht, F. Reyes, B. Coiffier, Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte Journal of Clinical Oncology. ,vol. 23, pp. 4117- 4126 ,(2005) , 10.1200/JCO.2005.09.131
Rhona Stein, M Jules Mattes, Thomas M Cardillo, Hans J Hansen, Chien-Hsing Chang, Jack Burton, Serengulam Govindan, David M Goldenberg, None, CD74: A New Candidate Target for the Immunotherapy of B-Cell Neoplasms Clinical Cancer Research. ,vol. 13, ,(2007) , 10.1158/1078-0432.CCR-07-1167
Jonathan W. Friedberg, Unique Toxicities and Resistance Mechanisms Associated with Monoclonal Antibody Therapy Hematology. ,vol. 2005, pp. 329- 334 ,(2005) , 10.1182/ASHEDUCATION-2005.1.329
Vibeke Hvidberg, Maciej B. Maniecki, Christian Jacobsen, Peter Højrup, Holger J. Møller, Søren K. Moestrup, Identification of the receptor scavenging hemopexin-heme complexes Blood. ,vol. 106, pp. 2572- 2579 ,(2005) , 10.1182/BLOOD-2005-03-1185
Naoko Yoshio-Hoshino, Yasuo Adachi, Chieko Aoki, Alexander Pereboev, David T. Curiel, Norihiro Nishimoto, Establishment of a New Interleukin-6 (IL-6) Receptor Inhibitor Applicable to the Gene Therapy for IL-6–Dependent Tumor Cancer Research. ,vol. 67, pp. 871- 875 ,(2007) , 10.1158/0008-5472.CAN-06-3641
M L Grossbard, J M Lambert, V S Goldmacher, N L Spector, J Kinsella, L Eliseo, F Coral, J A Taylor, W A Blättler, C L Epstein, Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. Journal of Clinical Oncology. ,vol. 11, pp. 726- 737 ,(1993) , 10.1200/JCO.1993.11.4.726
R Bataille, B Barlogie, ZY Lu, JF Rossi, T Lavabre-Bertrand, T Beck, J Wijdenes, J Brochier, B Klein, Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma Blood. ,vol. 86, pp. 685- 691 ,(1995) , 10.1182/BLOOD.V86.2.685.BLOODJOURNAL862685
Antonio J. Grillo-Lopez, Rituximab: an insider's historical perspective. Seminars in Oncology. ,vol. 27, pp. 9- 16 ,(2000)
C Kosmas, K Stamatopoulos, N Stavroyianni, K Zoi, C Belessi, N Viniou, P Kollia, X Yataganas, Origin and diversification of the clonogenic cell in multiple myeloma: lessons from the immunoglobulin repertoire Leukemia. ,vol. 14, pp. 1718- 1726 ,(2000) , 10.1038/SJ.LEU.2401908
Andreas Himmelmann, Agostino Riva, Gaye Lynn Wilson, Brian P. Lucas, Claire Thevenin, John H. Kehrl, PU.1/Pip and basic helix loop helix zipper transcription factors interact with binding sites in the CD20 promoter to help confer lineage- and stage-specific expression of CD20 in B lymphocytes Blood. ,vol. 90, pp. 3984- 3995 ,(1997) , 10.1182/BLOOD.V90.10.3984